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Abstract
Background: Outpatient drugs are dispensed through both community and mail order pharmacies. There is no
empirical evidence that substitution of community pharmacy with mail order reduces overall drug expenditures.
The need for evaluating the potential effects on utilization and costs of the possible extension of mail order
services in Medicaid provides the rationale for conducting this study. This study compares drug utilization and
drug product cost in community vs. mail order pharmacy dispensing services in a Medicaid population.
Methods: This study is a retrospective cohort study comparing utilization and cost patterns in community vs.
mail order pharmacy. A simulation model was employed to assess drug utilization and cost in mail order pharmacy
using community pharmacy claim data. The model assumed that courses of drug therapy (CDT) in mail order
pharmacy would have utilization patterns similar to those found in community pharmacy. A 95% confidence
interval surrounding changes in average utilization and average cost were estimated using bootstrap analysis. A
sensitivity analysis was performed by varying drug selection criteria and supply, fill point, and medication
possession ratio (MPR). Sub-analyses were performed to address differences between mail order and community
pharmacy related to therapeutic class and dual-eligible patients.
Data for the study derived from pharmacy claims database of Ohio Medicaid State program for the period January
2000-September 2004. Drug claims were aggregated to obtain a set of CDTs representing unique patient IDs and
unique drug products. Drug product cost estimates excluded dispensing fees and were used to estimate the cost
reduction required in mail order to become cost neutral in comparison with community pharmacy.
Results: The baseline model revealed that the use of mail order vs. community pharmacy would result in a 5.5%
increase in drug utilization and a 5.4% cost reduction required in mail order to become cost neutral. Results from
Ohio Medicaid drugs for chronic use revealed a 5.1% increase in utilization and a 4.9% cost reduction required to
become cost neutral in comparison with community pharmacy.
Conclusion: The results of the simulation model indicate that mail order pharmacy increases drug utilization and
can also increase drug product cost if the cost per unit is not reduced accordingly. Prior consideration should be
given to the patient population, day-supply, disease, therapy, and insurance characteristics to ensure the
appropriate use of mail order pharmacy services.
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Background
Outpatient drugs are dispensed through both community
and mail order pharmacies. In 2004, mail order pharma-
cies dispensed 214 million prescriptions, representing
6.5% of the prescriptions dispensed in the U.S. outpatient
pharmaceutical sector during that year [1]. Prescriptions
for mail order provide a 90-day supply as opposed to a 30-
day supply typically dispensed in community pharmacies.
When mail order prescriptions are converted to 30-day
supplies, mail order pharmacies can be viewed as having
dispensed an estimated 642 million prescriptions in
2004, representing 17.3% (up from 12% in 1994) of the
outpatient market. These numbers translate into $41.3
billion in sales, representing 18.7% of U.S. outpatient pre-
scription sales [1].
Initially, mail order pharmacy was perceived as an alterna-
tive for patients who use a high volume of prescription
drugs for chronic conditions [2-6] or for patients who can-
not access community pharmacy services [7,8]. Although
cost containment is the main reason behind the recent
development of mail order pharmacy [3,9,10], there is no
empirical evidence that substitution of community phar-
macy with mail order reduces overall drug expenditures.
Increases in utilization could result in higher overall pre-
scription drug expenditures for mail order pharmacy in
spite of a lower cost per unit. Previous studies found that
drug utilization in pharmacy benefit managers (PBM)
commercial populations was higher in mail order phar-
macy than in community pharmacy[3,9,10]. Higher drug
utilization in mail order pharmacies is attributed to an
established drug supply of 90 days and because the co-
payments associated with mail order are lower than those
associated with community pharmacy [11]. However, no
studies have been done to control for patient characteris-
tics that could influence utilization. For example, patients
that have better adherance to drug therapy could be more
inclined to select mail order pharmacy.
In addition, drug therapy discontinuation is frequent
regardless of the therapy utilized [12-18], and such dis-
continuation can lead to wastage in cases where patients
do not complete their drug regimens. Both increased uti-
lization and increased wastage (regardless of the reasons
for discontinuation) are expected in mail order pharmacy.
Moreover, as an incentive to use mail order pharmacy
services, higher co-payments, third-party rejections for
drug refills, and day-supply controls may be implemented
if a plan enrollee obtains the drug from a community
pharmacy.
The scope of this study is a Medicaid population. Mail
order services have been implemented in the Medicaid
programs of Maine and Washington [19], and multiple
states considered mail order as an alternative pharmacy
delivery system for their Medicaid programs. The need for
evaluating the potential effects on utilization and costs of
the possible extension of mail order services in Medicaid
provides the rationale for conducting this study. Addition-
ally, Medicaid/Medicare dual eligible patients included in
the Medicare Part D program after January 2006 are man-
aged by private plans, which use mail order services more
often.
Mail order services in Medicaid have not been examined
previously in the scientific literature. Medicaid differs
from traditional comercial plans in that benefits are con-
trolled at both the federal and state levels. Moreover, Med-
icaid programs are managed by the state departments with
PBM support for claims processing and other services.
Also, state Medicaid programs define their own pharmacy
reimbursement structures, including the estimated drug
acquisition cost and dispensing fees. Finally, Medicaid
drug pricing is specially influenced by pharmaceutical
company rebates, which are regulated at the federal level,
and most states have a supplemental rebate program.
The objectives of this study are: 1) to compare drug utili-
zation in a Medicaid population using community phar-
macy services with the results of a model simulating the
effect of mail order pharmacy in the same population; and
2) to estimate the mail cost reduction required to become
cost neutral in comparison with community pharmacy.
Methods
This study is a retrospective cohort study comparing utili-
zation and cost patterns in community and mail order
pharmacy. Drug utilization is defined in this study as the
day supply of drug product reimbursed by the Ohio Med-
icaid program A novel simulation model using commu-
nity pharmacy claim data was employed to assess drug
utilization in mail order pharmacy and mail order cost
reduction required to become cost neutral in comparison
with community pharmacy. The model used the course of
drug therapy (CDT) representing unique patient IDs and
unique drug products (i.e. generic name(s), formulation,
and strength(s)) as the unit of analysis. The cost was esti-
mated from the perspective of the Medicaid program.
Pharmacy claims data from the Ohio Medicaid program
for the period January 2000-September 2004, including
93.0 million unduplicated claims for patients who were
not institutionalized at any point during the study period
were used for the analysis (Table 1). The data set was
aggregated to obtain a final set of CDTs representing
unique patient IDs and unique drug products (i.e. generic
name(s), formulation, and strength(s)). The final data set
contained 18.5 million CDTs, with an average of fiveBMC Health Services Research 2007, 7:122 http://www.biomedcentral.com/1472-6963/7/122
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claims per CDT. The Ohio State University's Institutional
Review Board granted exemption for the study.
All CDTs initiated between August 2000 and July 2001
were selected for inclusion in the study. CDTs initiated
between January and July 2000 were excluded to ensure
that the drug therapy was newly provided (i.e. that
patients had not taken the therapy during the six months
prior to selection). Therapies initiated after July 2001 were
excluded to allow for a follow-up period of at least three
years and two months and to minimize right censoring
data issues. The baseline analysis excluded chronic drugs
for short-term use and included acute drugs for chronic
use.
The criteria for selecting the baseline sample from the
final data set was that, for each CDT, patients should have
utilized a supply of at least 90 days and should have main-
tained a Medication Possession Ratio (MPR) of at least
0.5. The MPR was estimated using the number of days
supply reimbursed by Ohio Medicaid according with the
information available in the claims data. Although the
MPR does not assess actual consumption, it is a proxy
measure of adherence that determines the proportion of
days a patient has medication available to be taken [20].
The MPR for each CDT was calculated by dividing the day
supply for all fills except the last fill by the total number
of days between the first and last fill. MPR values above
1.0 indicate that the patient is obtaining early refills, tak-
ing more medication than that provided in the defined
daily dosage, or the day supply was processed incorrectly
at the pharmacy.
The mail order simulations did not include the first fill,
because mail order pharmacy starts typically with the first
refill. The effect of mail order on drug utilization was cal-
culated for each CDT by dividing the MPR-adjusted com-
munity pharmacy day supply by 90 and rounding that
result to the next highest integer. Incremental changes in
drug utilization attributable to the effect of mail order
were estimated.
The methodology utilized in the mail order simulation
model can be illustrated by the following example (Table
2): In the case of a patient who has received 600 day sup-
ply after the first fill in community pharmacy during the
study period, who has also maintained a MPR of 1 for the
entire period, the 600 day supply is divided by 90 (given
that mail order pharmacy provides a 90 day supply for
each fill); the quotient is rounded to 7 (the next highest
integer); and the product of 90 and 7 is multiplied by the
MPR (i.e. 1), resulting in 630. The incremental change in
drug utilization attributable to the effect of mail order is
the difference between the 630 mail order day supply and
the 600-community-pharmacy day supply, that is, a posi-
tive 30 day supply representing a 5% increase in utiliza-
tion. Using the same example, a change in the MPR would
result in a different mail order utilization amount.
The mail order pharmacy cost reduction required to
become cost neutral in comparison with community
pharmacy were estimated by first calculating the drug
product cost per claim in community pharmacy; that is,
by deducting the Ohio State Medicaid dispensing fee of
$3.70 per claim. Next, community pharmacy drug prod-
uct cost per day of supply was calculated for each CDT by
dividing the drug product cost by the total number of days
the drug was supplied. It was assumed that drug product
cost in community and mail order pharmacy would be the
same. This assumption allowed for the estimation of cost
differences between both channels and the assessment of
the cost reduction that mail order should achieve to
become cost neutral. Hence, drug product cost in mail
order pharmacy was estimated by multiplying the mail
order day supply figure by the community pharmacy drug
product cost per day supply. Costs were not adjusted for
inflation or discounted. As with the estimates of drug uti-
lization, estimates of differences in drug product cost did
not take into account the day supply associated with
patients' first fill.
Once the incremental changes in utilization attributable
to the use of mail order were modeled and the mail order
cost reduction required to become cost neutral in compar-
ison with community pharmacy, a 95% confidence inter-
val surrounding these changes was constructed.
Specifically, bootstrap analysis, a non-parametric
approach used to avoid distributional assumptions [21]
was used to estimate the 95% confidence interval sur-
rounding estimated changes in average utilization and
average cost in order to address the lack of normality in
the distribution of the utilization and cost data.
Sub-analyses were performed in relation to drugs for
chronic conditions (as determined by State Medicaid drug
classifications), dual-eligible patients (Medicare/Medic-
aid patients), and that subset of dual-eligible patients
Table 1: Ohio Health Plans- Pharmacy Claim Data
Number % of Total
Institutionalized patient claims 39,028,913 29.55%
Community pharmacy claims 93,029,178 70.45%
Unduplicated claims 132,058,091 100.00%
Drug therapies (community pharmacy) 18,544,752
Average claims per drug therapy 5.02BMC Health Services Research 2007, 7:122 http://www.biomedcentral.com/1472-6963/7/122
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using drugs for chronic conditions. The sub-analyses uti-
lized a baseline sample based on the selection criteria
described above. Similar to the main analysis, sub-analy-
ses also calculated incremental changes in utilization
attributable to mail order and the mail order cost reduc-
tion required to become cost neutral in comparison with
community pharmacy.
Multivariate sensitivity analysis was performed in relation
to the baseline model by varying the following parame-
ters: 1) point where mail order filling was initiated (i.e.,
whether first fill, second fill, etc.), 2) minimum acceptable
MPR for a CDT being eligible for mail order, and 3) min-
imum day supply utilized in community pharmacy for a
CDT being eligible for mail order.
Results
The baseline model included 258,412 patients, 680,277
CDTs, and 869 drugs in 26 therapeutic classes. Demo-
graphic characteristics were estimated at the patient and
CDT levels (Table 3).
The distribution of number of day supply per CDT was
right-skewed for both community and mail order phar-
macy (Figures 1 and 2), reflecting a higher ratio of discon-
tinuation of drug therapies during the first year of therapy.
The final sample of 680,277 CDTs yielded a mean of
640.0 ± 515.0 day supply in community pharmacy and
the model for mail order resulted in 675.0 ± 518.0 day
supply (Table 4). The mean difference was estimated at
Table 3: Baseline Sample Characteristics
Variables Patients % of Patients CDT* % CDT
Observations 258,412 680,277
Gender
Female 169,219 65.50% 460,975 67.80%
Male 89,193 34.50% 219,302 32.20%
Average Age (Yrs.) 43.1(± 22.0) 49.4(± 20.0)
Ethnicity
White 200,231 77.50% 532,054 78.20%
Black 53,922 20.90% 137,949 20.30%
Asian 1,641 0.60% 3,859 0.60%
Other 2,618 1.00% 6,415 0.90%
Hispanic (of any race) 4,146 1.60% 9,683 1.40%
Program
Aged, Blind, and 
Disabled
104,348 40.40% 323,780 47.60%
Dual-Eligible 60,591 23.40% 199,902 29.40%
Healthy Start 64,703 25.00% 98,347 14.50%
Other 28,770 11.10% 58,248 8.60%
Note: CDT – Courses of Drug Therapy
Table 2: Effect of Medication Possession Ratio (MPR) on Mail Order Modeling Results
Example 1. MPR Equal to 1 Example 2. MPR Equal to 1.25 Example 3. MPR Equal to .75
CP MO Diff. CP MO Diff. CP MO Diff.
Total day supply 600 630 30 750 788 38 450 450 0
MPR 1.00 1.00 0.00 1.25 1.25 0.00 0.75 0.75 0.00
Days 600 630 30 600 630 30 600 600 0
Refills 20 7 -13 20 7 -13 15 5 -10
30-day-equivalent refills 20 21 1 20 21 1 15 15 0
Average day supply per refill 30 90 60 38 113 75 30 90 60
CP = Community Pharmacy; MO = Mail order pharmacy; Diff. = Difference
Note: Numbers are rounded to the next integer.BMC Health Services Research 2007, 7:122 http://www.biomedcentral.com/1472-6963/7/122
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35.3 days supply (95% confidence interval of the mean
difference = 32.5–35.3).
The mean cost in community pharmacy of the CDTs
included in the sample was $1,395.63 ± $5,982.19 and
the model for mail order resulted in a mean cost of
$1,471.62 ± $6,349.17. The mean mail order cost reduc-
tion required to become cost neutral in comparison with
community pharmacy was estimated at $75.99 (95% con-
fidence interval of the mean difference = $75.97–$77.00).
Thus, a 5.5% increase in drug utilization was associated
with the use of mail order. This increase in utilization
would lead to an estimated 5.4% mail order cost reduc-
tion required to become cost neutral in comparison with
community pharmacy over the follow-up period that
started in January 2000 and ended in July 2004 (Table 4).
When the sub-analysis on drugs classified by the Ohio
State Medicaid Program as drugs for chronic use was per-
formed, mail order resulted in an average day supply
increase of 34.8 days, representing a 5.1% increase in uti-
lization and a 4.9% cost reduction required to become
cost neutral (Table 5). The use of mail order by dual-eligi-
ble patients was estimated to result in a day supply
increase of 35.4 days, representing a 4.7% increase in uti-
lization and a 4.7% cost reduction required to become
cost neutral Finally, the use of mail order by dual-eligible
Table 4: Changes in Utilization and Cost Attributable to Mail Order. Baseline Model (n = 680,277)
Mean Std Dev Confidence Interval of the Mean Difference (95%)
Lower Upper
Day supply in community pharmacy 640.0 515.0
Estimated day supply in mail order pharmacy 675.0 518.0
Difference 35.3 35.2 35.3
% Difference 5.52%
Drug product cost in community pharmacy $1,395.63 $5,982.19
Estimated drug product cost in mail order pharmacy $1,471.62 $6,349.17
Mail order cost reduction required to become cost neutral $75.99 $75.97 $77.00
% Difference 5.44%
Note: Utilization and costs after the first fill.
Distribution of day supply per CDT Figure 1
Distribution of day supply per CDT. Community pharmacy.
 Day  Supply
Percentage 
of CDTs 
Simulated distribution of day supply per CDT Figure 2
Simulated distribution of day supply per CDT. Mail order.
Estimated Day Supply
Percentage 
of CDTs BMC Health Services Research 2007, 7:122 http://www.biomedcentral.com/1472-6963/7/122
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consuming drugs for chronic use was estimated to result
in a day supply increase of 34.8 days, representing a 4.3%
increase in utilization and a 4.4% cost reduction required
to become cost neutral. The difference between the base-
line analysis and the sub-analyses is due to the increase in
average day supply per CDT.
The model was sensitive to assumptions related to the
minimum community pharmacy day supply required for
mail order eligibility (Table 6). Keeping all other baseline
variables constant, drug utilization in mail order
increased 7.1% when the minimum day supply required
for mail order eligibility was assumed to be 30. The incre-
mental increase in utilization fell below 5% when the
minimum day supply required for mail order eligibility
was increased to 180 days or when the minimum MPR
was increased to 0.75.
Discussion
In this study a model was developed to assess utilization
and drug costs to compare community and mail order
pharmacy services using the same group of patients. Dif-
ferences in drug utilization for mail order and community
pharmacy as shown in the model are consistent with find-
ings from previous studies that found an increase in utili-
zation associated with the use of mail order
pharmacy[3,9,10] These findings were gleaned from the
comparison of two groups of patients from the same plan,
one group using mail and other group using community
pharmacy services. The simulation model in this study
was developed using a case-crossover design within the
specific parameters of a Medicaid population, thus mini-
mizing the chance of selection bias.
The results of the sub-analyses indicate that the increase in
drug utilization in mail order remained relatively constant
(at a day supply of approximately 35 days) regardless of
the sample utilized (i.e., all CDTs, CDTs utilizing drugs
for chronic conditions, or CDTs observed in dual-eligible
patients). Nevertheless, an increase in total day supply per
CDT was observed in the sub-analyses, which resulted in
a lower relative difference in utilization in mail order vs.
community pharmacy. This reduction in the utilization
relative difference has implications for mail order's
impact on cost: The lower the overall relative difference in
utilization, the lower the overall difference in unit cost
must be for mail order pharmacy to become cost-neutral.
The results of the sensitivity analysis indicate that a reduc-
tion in the minimum number of day supply the CDTs
were utilized in community pharmacy to become eligible
for mail order increased the difference in utilization
between mail order and community pharmacy. This result
was the expected because the reduction in the number of
day supply allowed for inclusion in the model of medica-
tions used for short term purposes. Finally, increases in
the MPR reduced utilization relative differences, indicat-
ing that mail order is more appropriate for patients with
high compliance.
Information about the unit cost of mail order in Medicaid
is not available therefore, we assumed that the cost would
be the same in mail and in community pharmacy regard-
ing the estimation of the breakeven point; that is the cost
reduction required in mail order to become cost neutral in
comparison with community pharmacy. The results of
our study indicate that mail order cost should be reduced
in 5.4% to breakeven with the cost in community phar-
macy.
Mail order pharmacy has cost advantages and disadvent-
ages over community pharmacy. First, dispensing a 90 day
supply prescription instead of three 30 day supply pre-
scriptions reduces dispensing costs for mail order opera-
tions. However, this reduction in dispensing costs could
also be expected in community pharmacy if a 90 day sup-
Table 5: Changes in Utilization and Cost Attributable to Mail Order. Drugs for Chronic Use and Dual-Eligible
Drugs for Chronic 
Use (n = 304,102)
Dual-Eligible (n = 199,902) Dual-Eligible Using Drugs for 
Chronic Use (n = 96,868)
Mean Std Dev Mean Std Dev Mean Std Dev
Day supply in community pharmacy 687.6 523.2 758.8 527.8 807.0 526.7
Estimated day supply in mail order pharmacy 722.4 525.2 794.2 530.1 841.8 528.7
Difference 34.8 35.4 34.8
% Difference 5.1% 4.7% 4.3%
Drug product cost in community pharmacy $1,103.65 $2,918.83 $1,563.01 $7,114.38 $1,219.59 $2,139.52
Estimated drug product cost in mail order pharmacy $1,157.30 $3,039.04 $1,635.63 $7,531.51 $1,272.62 $2,226.44
Mail order cost reduction required to become cost neutral $53.65 $72.62 $53.03
% Difference 4.9% 4.7% 4.4%
Note: Utilization and costs after the first fillBMC Health Services Research 2007, 7:122 http://www.biomedcentral.com/1472-6963/7/122
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ply were dispensed instead of a 30 day supply. Second,
large mail order operations may have lower drug product
acquisition cost than the average community pharmacy.
With commercial plans, the cost per unit is lower in mail
order than in community pharmacy due to a reduction in
drug product cost, lower dispensing fees and higher
rebates. However, mail order pharmacy could experience
higher overall cost per CDT for the Medicaid program if
drug product costs, supplemental rebates and/or dispens-
ing fees are not adjusted accordingly with the increase in
utilization. In addition, wholesaler distribution and
inventory costs may also be lower in mail order pharmacy
than in community pharmacy. However, mail order phar-
macy has costs that are not found in community phar-
macy, including packaging, mailing, and special handling
costs, and the cost of drugs lost in mail.
Third, plan benefits may be structured according to phar-
macy characteristics and geographical area. For example,
pharmacy reimbursement in the Medicaid programs of
Maine and Washington is lower for mail order than for
community pharmacy (Table 7). An examination of the
effect of mail order on pharmacy expenditures for these
two programs would require the analysis of the estimated
acquisition costs, professional and dispensing fees, co-
payments, and administrative costs paid by the programs.
Additionally, the study does not account for drug cost
management tools that are implemented to some extent
differently at mail and community pharmacies.
Table 7: Medicaid Pharmaceutical Reimbursement Structure in Maine and Washington, Quarter Ending March 2006
Maine Washington
Drug Product Cost Community
General: AWP-15%
Direct supply drug list:*
Usual & customary charge or AWP-17% plus $3.35 professional 
fee or FUL or MAC plus $3.35 professional fee
Mail order
Lowest of: usual & customary charge, AWP-20% plus $1.00 
professional fee, or FUL or MAC plus $1.00 professional fee
Community
AWP-14% single source & multiple source (w/2–4 
manufacturers) AWP-50% multiple source from 5+ 
manufactures
Mail order
AWP-19% (brand-mail order), AWP-15% (generic-mail 
order)
Dispensing Fee Community and Mail Order
$3.35; $4.35 5.35(compounding);$12.50 (insulin syringe)
Community
$4.20–$5.20
Mail order
$3.25
Co-Payment Community
$2.50 generic & brand, not to exceed
$25/mo.
Mail order
None
Community and Mail Order
None
*Note: AWP = average wholesaler price; FUL = Federal Upper Limit; MAC= maximum allowable cost. Direct Supply Drug List: list of covered 
drugs consisting of certain maintenance drugs including specialty drugs, caloric supplements and substitutes and medical foods. Source: Centers for 
Medicare and Medicaid Services, 2006.
(Centers for Medicare & Medicaid Services 2006)
Table 6: Sensitivity Analysis
Scenario Minimum MPR Fill at Which Mail 
Order Is Initiated
Minimum Community 
Pharmacy Day Supply Required 
for Mail Order Eligibility
Incremental Change in 
Drug Utilization (%)
Mail order cost reduction required 
to become cost neutral (%)
Baseline 0.50 2 90 5.5% 5.4%
1 0.33 2 90 6.1% 6.0%
2 0.50 1 90 5.4% 5.3%
3 0.50 2 30 7.1% 7.1%
4 0.50 2 60 6.4% 6.3%
5 0.50 2 120 5.2% 5.2%
6 0.50 2 150 5.1% 5.0%
7 0.50 2 180 4.8% 4.7%
8 0.50 3 90 5.9% 5.9%
9 0.75 2 90 4.2% 4.2%BMC Health Services Research 2007, 7:122 http://www.biomedcentral.com/1472-6963/7/122
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The CDT selection criteria used in the study were designed
to restrict the sample to those CDTs that would be more
appropriate for mail order. First, only CDTs in which the
patient had utilized the drug for at least 90 days during the
study period were selected. In practice, this is an ex-post
criterion, as mail order pharmacists would not have this
information prior to any decision to initiate mail order
dispensing; this criterion is also consistent with mail order
in that those medications discontinued immediately after
the first refill were excluded. Second, the study utilized
only those CDTs in which the patient maintained a mini-
mum MPR of 0.5 during the study period. The study's
CDT selection criteria allowed for the exclusion of drugs
that were used during multiple periods of time (e.g. med-
ication for allergy) and for short-term purposes (e.g. anti-
biotics). Third, the model assumes that the MPR
associated with mail order pharmacy is the same as that
observed in community pharmacy. In fact, however, mail
order could increase the MPR given that patients have
more medication available when 90-day supplies (vs. the
30-day supplies used in community pharmacy) are dis-
pensed. Another assumption of the model is that mail
order begins with the second fill; initiation of mail order
at the first fill would further increase utilization given the
high rate of therapy discontinuation that occurs before the
second fill is dispensed. Fourth, the model also assumes
that the drug supplies dispensed in mail order pharmacy
are MPR-adjusted 90-day supplies. In fact, mail order pro-
grams can dispense supplies of 120 days or more.
Increases in day supply would increase the difference in
utilization in mail order vs. community pharmacy. And
fifth, the baseline sample included all medications suita-
ble for mail order, regardless of their classification and
therapeutic category. To assess the validity of the criteria
used to select these drugs, a sub-analysis was performed in
relation to those drugs classified by the Ohio State Medic-
aid program as drugs for chronic use. A sub-analysis
related to the dual-eligible population was also performed
as this population of Ohio Medicaid patients are eligible
for the new Medicare prescription drug program that
began in 2006. A final sub-analysis included the subset of
dual-eligible patients using drugs for chronic conditions.
The three sub-analyses conducted in this study yielded
similar increases in utilization derived from the use of
mail order pharmacy.
Patients included in the study could have gaps in cover-
age; exclusion of these patients would misrepresent the
potential effect of mail order pharmacy in the Medicaid
program. Given a high turnover rate, periods of fluctuat-
ing coverage, and therapy discontinuation for enrollees
associated with the Medicaid program, caution should be
applied when generalizing these findings to other popula-
tions. In addition, the study only included drug reim-
bursement (drug product costs and dispensing fees); non-
health care costs, such as patient costs to pick up medica-
tion at a local pharmacy, acquisition of medications
through channels outside the scope of this study, and
indirect costs were excluded from the analysis.
This study did not discount drug costs or adjust them for
inflation. Discounting would have increased the cost dif-
ferences resulting from mail order in that mail order pay-
ments are for three-month supplies as opposed to the
one-month supplies used in community pharmacy.
Adjusting drug costs for inflation would have reduced cost
differences for the same reason. However, the study
results would not change had these adjustments occurred.
Finally, this study does not evaluate the effect of increas-
ing utilization on patients' outcomes. While higher utili-
zation could result in higher patient compliance with
drug treatments and increased access to drugs, this link
has not been established in the available mail order phar-
macy literature. Future research is needed to examine ther-
apy discontinuation and estimation of drug wastage,
resulting from medications that were not used because of
tolerability issues, medication changes, ineffectiveness,
and wastage attributed to other factors such as mail mis-
haps, spoilage, and patient failure to pickup rates, and an
analysis of the impact of mail order pharmacy utilization
on patient health outcomes. Future studies should also
evaluate if the increase in utilization associated to mail
order pharmacy could improve medication adherence
and if adherence rates vary in different groups of Medicaid
beneficiaries.
While the scope of this study is the Medicaid population,
the results of the model related with increases in utiliza-
tion can be also applicable to PBM commercial popula-
tions. Evaluation of mail order in a commercial
population should evaluate if the reduction in costs per
unit justifies the increase in utilization.
Conclusion
The results of the simulation model used in this study
indicate that mail order pharmacy increases drug utiliza-
tion and can increase drug product cost if the cost per unit
is not reduced accordingly. These results were achieved
with CDT selection criteria that were designed to restrict
the sample to only those CDTs for which the dispensing
of 90-day supplies was appropriate.
Although increases in utilization may be beneficial for cer-
tain patients and may be linked to increases in medication
adherence, policymakers should evaluate the utilization
and cost effects that result from the implementation of
mail order pharmacy programs. In addition, any program
that increases the number of day supply dispensed to the
patients should carefully target specific populations andPublish with BioMed Central    and   every 
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therapies whose potential savings and/or health out-
comes overcome the potential extra costs that result from
increased utilization and wastage. Although, mail order is
expected to have a large role in the Medicare Part D pro-
gram, data are not yet available for analysis. Projections
from this study reveal an increase in utilization attributed
to mail order should be expected, and mail order services
would be more appropriate for patients using mainte-
nance drug therapies for chronic conditions for long peri-
ods of time (more than 2 years). In addition, mail order
pharmacy services could facilitate access to medications
for underserved areas and for elderly and disabled popu-
lations. This potential impact on access should be consid-
ered when evaluating the overall effect of mail order
pharmacy.
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